Drrx stock forecast.
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.
The forecasts range from a low of 32.32 to a high of $46.20. ... The put/call ratio of DRRX is 2.53, ... Vanguard Total Stock Market Index Fund Investor Shares holds 6,635K shares representing 27. ...View DURECT Corporation DRRX investment & stock information. Get the latest DURECT Corporation DRRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.DRRX Stock 12 Months Forecast. $8.50. (1187.88% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Durect in the last 3 months. The average price target is $8.50 with a high forecast of $8.50 and a low forecast of $8.50. The average price target represents a 1187.88% change from the last price of $0.66.DURECT Corp ( DRRX) is up 3.29% today. DRRX has an Overall Score of 75. Find out what this means to you and get the rest of the rankings on DRRX! DRRX stock closed at $7.00 and is up $0.23 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours.
Based on 2 Wall Street analysts offering 12 month price targets for Biolase in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 244.83% change from the last price of $1.16. Highest Price Target $4.00. Average Price Target $4.00.
Get the latest Dare Bioscience Inc (DARE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for First Wave BioPharma Inc have a median target of 11.00, with a high estimate of 11.00 and a low estimate of 11.00. The ...
On June 7, 2023, DURECT Corporation announced the successful completion of enrollment for Phase 2b AHFIRM clinical trial. The trialSNBR Stock Outlook. Sleep Number updated its outlook for the full year of 2023 in its latest earnings report as well. It now expects diluted EPS to be up to -70 cents while revenue will decrease ...On average, Wall Street analysts predict that Durect 's share price could reach $34.00 by Aug 10, 2024. The average Durect stock price prediction forecasts a potential upside …(See DRRX stock forecast) Ovid Therapeutics . Next up is Ovid Therapeutics, a biopharmaceutical company working to develop new medications for the treatment of rare neurological disorders, ...Find the latest Oncology Pharma Inc. (ONPH) stock quote, history, news and other vital information to help you with your stock trading and investing.
(See DRRX stock forecast) Ovid Therapeutics . Next up is Ovid Therapeutics, a biopharmaceutical company working to develop new medications for the treatment of rare neurological disorders, ...
"DRRX" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "DRRX" projections. At Walletinvestor.com we …
However, it does not forecast the overall direction of its price. In a nutshell, if Durect's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Durect stock will not fluctuate a lot when Durect's options are near their ...Durect (NASDAQ: DRRX) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency ...Durect Corp Price (DRRX) Daily Price Prediction ChartsDRRX Stock Price Forecast. The average stock forecast for DURECT Corp (DRRX) in the next 12 months is 30.40 USD. This price target corresponds to an upside of 10.83%. The range of stock forecasts for DRRX is 12.12 - 43.05 USD. …Durect Corp (DRRX) $0.66 0.01 (1.54%) 13:00 EST DRRX Stock Quote Delayed 30 Minutes.DRRX, Durect - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. RESEARCH. Shopping Cart. Your cart is ... Durect (DRRX) - Develops pharmaceuticals for chronic pain and central nervous system disorders. GROUP LEADERSHIP Medical-Biomed/Biotech Group. DRRX. is not ranked …
DRRX: anyone following this stock? It's had quite an amazing run. The OI on the 2.5 dollar jan calls is quite high (much higher than the corresponding puts), and there seems to be two catalysts around the corner with the adcom at Jan 16 as well as the data for Dur-928 due either by the end of this year or early Jan next year. The adcom was ...View live DURECT Corporation chart to track its stock's price action. Find market predictions, DRRX financials and market news.DRRX Stock 12 Months Forecast. $8.50. (1187.88% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Durect in the last 3 months. The average …Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for DURECT stock is $36.5, which predicts an increase …
Nov 8, 2023 · DRRX Stock Performance on November 8, 2023: On November 8, 2023, DRRX stock had a volatile day of trading. The stock opened at $0.83 and traded in a range of $0.58 to $0.83 throughout the day. The trading volume was 693,861 shares. DRRX is a pharmaceutical company based in Cupertino, California, with a market capitalization of $75.3 million.
DRRX stock has massive potential and is up 32% so far this year. Analysts have a price target of $34.50, which would be a lofty 650% bump. DRRX stock has a “B” rating in the Portfolio Grader.SNBR Stock Outlook. Sleep Number updated its outlook for the full year of 2023 in its latest earnings report as well. It now expects diluted EPS to be up to -70 cents while revenue will decrease ...The shares of common stock and accompanying warrants are being sold at a combined purchase price of $5.00 per share and accompanying warrant, and the pre-funded warrants are being sold at a ...DRRX stock forecast Our latest prediction for Durect Corp's stock price was made on the May 26, 2020 when the stock price was at 2.66$. In the short term (2weeks), DRRX's stock price should outperform the market by 4.58%. During that period the price should oscillate between -11.17% and +17.56%.Nov 8, 2023 · DRRX Stock Performance on November 8, 2023: On November 8, 2023, DRRX stock had a volatile day of trading. The stock opened at $0.83 and traded in a range of $0.58 to $0.83 throughout the day. The trading volume was 693,861 shares. DRRX is a pharmaceutical company based in Cupertino, California, with a market capitalization of $75.3 million. DURECT (NASDAQ:DRRX) stock price plunges 31% as it entered into definitive agreements for the purchase and sale of an aggregate of 2.99M shares of common stock and warrants to purchase up to 2.99M ...DURECT Corp ( DRRX) is up 3.29% today. DRRX has an Overall Score of 75. Find out what this means to you and get the rest of the rankings on DRRX! DRRX stock closed at $7.00 and is up $0.23 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours.Based on 2 Wall Street analysts offering 12 month price targets for Biolase in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 244.83% change from the last price of $1.16. Highest Price Target $4.00. Average Price Target $4.00. DURECT Announces 1-for-10 Reverse Stock Split. CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX ), a biopharmaceutical company focused on developing epigenetic ...Dec 1, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...
Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43 ...
eCommerce double-digit growth in Q3 and share buyback of $18.6M. Raised 2023 Adjusted EBITDA range to $75M - $82M and Non-GAAP Net Income range to $7M - $12M.
DRRX stock recorded 20/30 (67%) green days with 62.91% price volatility over the last 30 days. Based on our DURECT stock forecast, it's now a bad time to buy DRRX stock because it's trading 19.19% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only. Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Get the latest DURECT Corp (DRRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Find the latest BioSig Technologies, Inc. (BSGM) stock quote, history, news and other vital information to help you with your stock trading and investing.The Durect stock forecast is 1.3653368157524 USD for 2024 November 26, Tuesday; and 6.830 USD for 2028 November 26, Sunday with technical analysis. Durect (DRRX) stock price prediction is 1.3653368157524 USD.DURECT Co. (NASDAQ:DRRX – Free Report) – Northland Capmk boosted their FY2023 EPS estimates for shares of DURECT in a report issued on Tuesday, November 14th. Northland Capmk analyst C. Byrnes now anticipates that the specialty pharmaceutical company will post earnings per share of ($1.47) for the year, up from …If you’re looking for stocks under $10 to buy, you can do a lot worse than these highly-rated picks. BBAI. BigBear.ai. $4.05. APPH. AppHarvest. $0.95. DRRX. Durect.DRRX Stock Price Forecast. The average stock forecast for DURECT Corp (DRRX) in the next 12 months is 30.40 USD. This price target corresponds to an upside of 10.83%. The range of stock forecasts for DRRX is 12.12 - 43.05 USD. …
With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.for development and commercialization in other countries. ****CYTR (T/$10) scleroderma etal... DRRX (T/$3) Durect Corp... ... But don't expect its stock price to ...In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.Instagram:https://instagram. forex vs stock marketguidewire stockshow to determine if gold is realapp to invest in real estate Oct 19, 2023 · The stock’s $2.58 trading price and $29.80 average price target reflects the high potential of the leading drug candidate – and implies a gain of 1,064% in the coming year. (See DRRX stock ... For DURECT stock forecast for 2026, 12 predictions are offered for each month of 2026 with average DURECT stock forecast of $0.87, a high forecast of $1.25, and a low forecast of $0.48. The average DURECT stock forecast 2026 represents a 39.89% increase from the last price of $0.620000004768372. meda sharedpst etf Durect Corp (DRRX) $0.66 0.01 (1.54%) 13:00 EST DRRX Stock Quote Delayed 30 Minutes. apex trading review DRTT one year forecast. DIRTT Environmental Solutions stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast DRTT stock forecast for 2023 – 2027. Last updated: November 25, 2023. ... Other companies stock forecasts. DRRX Stock Forecast; DRQ Stock Forecast;DRRX stock has a “B” rating in the Portfolio Grader. Dynavax Technologies (DVAX) Dynavax Technologies DVAX is a commercial-stage biotech company focusing is on getting drugs over the finish line (approval from the Food & Drug Administration and other regulators in other countries) and available for sale.